# Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

> **NCT00402116** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 72 (actual)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme
- Gliosarcoma

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** temozolomide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00402116
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402116, "Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00402116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*